Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PER2 | O15055 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24687997 | 0.86 | BRD4 (0.39) | PIK3CDPER2ALDH1A1MAPTBRD4 | |
| SCHEMBL1106515 | 0.86 | BRD4 (0.39) | PIK3CDPER2ALDH1A1MAPTBRD4 | |
| SCHEMBL596921 | 0.84 | PER2 (0.38) | PIK3CDPER2ALDH1A1MAPTCRY2 | |
| SCHEMBL7315310 | 0.83 | PIK3CD (0.35) | PIK3CDBRD4BRD2 | |
| SCHEMBL28424905 | 0.81 | PIK3CD (0.34) | PIK3CDPER2BRD4BRD2CRY2 | |
| SCHEMBL24568171 | 0.81 | PIK3CD (0.34) | PIK3CDBRD4BRD2 | |
| SCHEMBL23921706 | 0.81 | PIK3CD (0.34) | PIK3CDBRD4BRD2 | |
| SCHEMBL12890580 | 0.78 | PIK3CD (0.35) | PIK3CDALDH1A1MAPTBRD4BRD2 | |
| SCHEMBL9123416 | 0.78 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL12129129 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024137852-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2024116207-A1 | ADAR1 INHIBITORS AND METHODS OF USING THE SAME | AVAMMUNE THERAPEUTICS INC. (IN) | 2024-06-06 | — | — | WO | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20080287440-A1 | Novel Antifungal Triazole Derivatives | DAEWOONG PHARMACEUTIDCAL CO., LTD. (KR) | 2008-11-20 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| US-20080027093-A1 | Cyclohexylalanine Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-01-31 | — | — | US | disclosed |
| EP-0718291-B1 | Method for the preparation of triazole compounds | CHUGAI PHARMACEUTICAL CO LTD (JP) | 1998-07-08 | — | — | EP | disclosed |
| US-5567825-A | Method for the preparation of a triazole compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1996-10-22 | — | — | US | disclosed |
| EP-0718291-A1 | Method for the preparation of triazole compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1996-06-26 | — | — | EP | disclosed |
| EP-0280781-B1 | PROCESS FOR THE PREPARATION OF N-ALKYL-N'-METHYL-CYCLIC UREAS, ESPECIALLY N,N'-DIMETHYLCYCLIC UREAS | HÜLS AKTIENGESELLSCHAFT (DE) | 1991-09-18 | — | — | EP | disclosed |
| US-4864026-A | Method of manufacturing N-alkyl-N'-methyl-alkyleneureas, particularly N,N'-d | HULS AKTIENGESELLSCHAFT (DE) | 1989-09-05 | — | — | US | disclosed |
| EP-0280781-A1 | Process for the preparation of N-alkyl-N'-methyl-cyclic ureas, especially N,N'-dimethylcyclic ureas | HÜLS AKTIENGESELLSCHAFT (DE) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | PIK3CD 1372/4885PER2 1231/4885ALDH1A1 2989/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | PIK3CD 1678/4885PER2 4315/4885ALDH1A1 2230/4885 |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | PIK3CD 3769/4885PER2 3245/4885ALDH1A1 945/4885 |
| US-20080027093-A1 | Cyclohexylalanine Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | PIK3CD 2873/4885PER2 2100/4885ALDH1A1 1691/4885 |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | BRDT, BET1, BRD4 | PIK3CD 3717/4885PER2 2554/4885ALDH1A1 3230/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CD 321/4885PER2 4086/4885ALDH1A1 2776/4885 |
| US-20080287440-A1 | Novel Antifungal Triazole Derivatives | CYP51A1, ERG28, CYP3A43 | PIK3CD 651/4885PER2 4559/4885ALDH1A1 544/4885 |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | PIK3CD 3098/4885PER2 3003/4885ALDH1A1 4019/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | PIK3CD 4805/4885PER2 916/4885ALDH1A1 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.